Trending intel short linkNo signup · Email subscription
47.1k following · Pharmaceutical / FDA / Oncology Drug

FDA approval timeline for GSK's acquisition of Nuvalent's lung cancer inhibitors

Follow up on the FDA PDUFA approval progress and result changes of the two next-generation ROS1/ALK lung cancer inhibitors obtained by GSK through the acquisition of Nuvalent.

47.1k following94.4k views
By clicking “Confirm”, you acknowledge that you have read and agree to
/ /
Unlimited Free Public IntelligenceOnly key changes trigger emailsUnsubscribe anytime
Monitor official signalsTrack announcements, filings, company statements, prices, and investor updates.
AI summaryFilter repeated noise and provide concise conclusions with source confidence.
Notify only when usefulNo daily spam. You only get emailed when meaningful progress appears.